SCHEMBL1549916

SCHEMBL1549916

CCN(c1cc[nH]n1)c1nc(-c2ccc(N(C)C)c(C)c2)cc2ncccc12

nearest known ligand 0.47

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
SYK P43405 20/20 0.47
TXK P42681 1/20 0.35
KARS1 Q15046 1/20 0.35
SLK Q9H2G2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13478596 0.76 SYK (0.52) SYKTXKKARS1SLK
SCHEMBL1549984 0.74 SYK (0.51) SYK
SCHEMBL1550203 0.74 SYK (0.50) SYKTXKKARS1SLK
SCHEMBL16520293 0.74 SYK (0.50) SYKTXKKARS1SLK
SCHEMBL1550408 0.74 SYK (0.50) SYKTXKKARS1SLK
SCHEMBL16520292 0.71 SYK (0.47) SYKTXKKARS1SLK
SCHEMBL1549956 0.71 SYK (0.44) SYK
SCHEMBL1550178 0.68 SYK (0.52) SYKTXKKARS1SLK
SCHEMBL12235411 0.68 SYK (0.53) SYK
SCHEMBL1550002 0.68 SYK (0.53) SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2313406-B1 4-DIMETHYLAMINOPHENYL SUBSTITUTED NAPTHTHYRIDINES UND THEIR USE AS MEDICINE BOEHRINGER INGELHEIM INT (DE) 2015-02-25 EP disclosed
US-8957088-B2 4-dimethylamino-phenyl-substituted naphthyridines, and use thereof as medicaments BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-02-17 US disclosed
US-20140142135-A1 4-DIMETHYLAMINO-PHENYL-SUBSTITUTED NAPHTHYRIDINES, AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-05-22 US disclosed
US-8604049-B2 4-dimethylamino-phenyl-substituted naphthyridines, and use thereof as medicaments BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-12-10 US disclosed
US-20110263549-A1 4-DIMETHYLAMINO-PHENYL-SUBSTITUTED NAPHTHYRIDINES, AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-10-27 US disclosed
EP-2313406-A2 4-DIMETHYLAMINOPHENYL SUBSTITUTED NAPTHTHYRIDINES UND THEIR USE AS MEDICINE Boehringer Ingelheim International GmbH (DE) 2011-04-27 EP disclosed
WO-2010015518-A2 4-DIMETHYLAMINO-PHENYL-SUBSTITUTED NAPHTHYRIDINES, AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNTIONAL GMBH (DE) 2010-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263549-A1 4-DIMETHYLAMINO-PHENYL-SUBSTITUTED NAPHTHYRIDINES, AND USE THEREOF AS MEDICAMENTS NR4A3, NR4A1, NR1I3 SYK 1428/4885TXK 3844/4885KARS1 1629/4885
US-20140142135-A1 4-DIMETHYLAMINO-PHENYL-SUBSTITUTED NAPHTHYRIDINES, AND USE THEREOF AS MEDICAMENTS HRH1, HRH4, HRH2 SYK 386/4885TXK 1130/4885KARS1 1003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.